PMID- 23607087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2213-4344 (Print)
IS  - 2213-4344 (Electronic)
IS  - 2213-4344 (Linking)
VI  - 1
IP  - 2
DP  - 2013 Apr
TI  - Role of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice.
PG  - 41-49
AB  - Nutrition plays a minor role in psychiatric practice which is currently dominated 
      by a pharmacological treatment algorithm. An accumulating body of evidence has 
      implicated deficits in the dietary essential long-chain omega-3 (LCn-3) fatty 
      acids, eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the 
      pathophysiology of several major psychiatric disorders. LCn-3 fatty acids have an 
      established long-term safety record in the general population, and existing 
      evidence suggests that increasing LCn-3 fatty acid status may reduce the risk for 
      cardiovascular disease morbidity and mortality. LCn-3 fatty acid supplementation 
      has been shown to augment the therapeutic efficacy of antidepressant, 
      mood-stabilizer, and second generation antipsychotic medications, and may 
      additionally mitigate adverse cardiometabolic side-effects. Preliminary evidence 
      also suggests that LCn-3 fatty acid supplementation may be efficacious as 
      monotherapy for primary and early secondary prevention and for perinatal 
      symptoms. The overall cost-benefit ratio endorses the incorporation of LCn-3 
      fatty acids into psychiatric treatment algorithms. The recent availability of 
      laboratory facilities that specialize in determining blood LCn-3 fatty acid 
      status and emerging evidence-based consensus guidelines regarding safe and 
      efficacious LCn-3 fatty acid dose ranges provide the infrastructure necessary for 
      implementation. This article outlines the rationale for incorporating LCn-3 fatty 
      acid treatment into psychiatric practice.
FAU - McNamara, Robert K
AU  - McNamara RK
AD  - Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar 
      Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 
      45219-0516.
FAU - Strawn, Jeffrey R
AU  - Strawn JR
LA  - eng
GR  - R01 AG034617/AG/NIA NIH HHS/United States
GR  - R01 DK097599/DK/NIDDK NIH HHS/United States
GR  - R34 MH083924/MH/NIMH NIH HHS/United States
GR  - UL1 TR000077/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - Netherlands
TA  - PharmaNutrition
JT  - PharmaNutrition
JID - 101602522
PMC - PMC3628733
MID - NIHMS438070
OTO - NOTNLM
OT  - ADHD
OT  - Anxiety
OT  - Bipolar disorder
OT  - Cardiovascular disease
OT  - Clinical staging
OT  - Docosahexaenoic acid (DHA)
OT  - Eicosapenaenoic acid (EPA)
OT  - Long-chain omega-3 fatty acids
OT  - Major depressive disorder
OT  - Primary prevention
OT  - Schizophrenia
OT  - Suicide
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
PMCR- 2014/04/01
CRDT- 2013/04/23 06:00
PHST- 2013/04/23 06:00 [entrez]
PHST- 2013/04/23 06:00 [pubmed]
PHST- 2013/04/23 06:01 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - 10.1016/j.phanu.2012.10.004 [doi]
PST - ppublish
SO  - PharmaNutrition. 2013 Apr;1(2):41-49. doi: 10.1016/j.phanu.2012.10.004.